A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency

Official Title

TRITON3: A Multicentre, Randomized, Open Label Phase 3 Study of Rucaparib Versus Physician's Choice of Therapy for Patients With Metastatic Castration Resistant Prostate Cancer Associated With Homologous Recombination Deficiency


The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer, and evidence of a homologous recombination gene deficiency, respond to treatment with rucaparib versus treatment with physician's choice of abiraterone acetate, enzalutamide, or docetaxel.

Trial Description

Primary Outcome:

  • Radiographic Progression-free Survival (rPFS)
Secondary Outcome:
  • Overall Survival
  • Objective Response Rate (ORR)
  • Duration of Response (DOR)
  • Time to Prostate Specific Antigen (PSA) Progression
  • PSA Response
  • Change in Patient-reported Outcome (PRO)
  • Clinical Benefit Rate (CBR), defined as the percentage of patients with a complete response (CR), partial response (PR), and stable disease (SD) according to modified RECIST Version 1.1 with no progression in bone per PCWG3 criteria
  • Trough plasma PK (Cmin) of rucaparib based on sparse sampling
  • Number of participants with Adverse Events (AEs) as a measure of safety and tolerability

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society